2-(3-oxo-3H-benzo[d]isothiazol-2-yl)-benzoic acid | 4322-94-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 2-(3-oxo-3H-benzo[d]isothiazol-2-yl)-benzoic acid
• 英文别名: 2-(2-carboxy-phenyl)-benzisothiazol-3-one；2-(3-oxo-1,2-benzisothiazol-2(3H)-yl)benzoic acid；2-(3-oxo-1,2-benzothiazol-2-yl)benzoic acid
• CAS: 4322-94-5
• 化学式: C₁₄H₉NO₃S
• mdl: MFCD23568757
• 分子量: 271.296
• InChiKey: CPHHUVGXQLAMDM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  82.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2,2-二硫二苯甲酰氯 、 邻氨基苯甲酸 生成 2-(3-oxo-3H-benzo[d]isothiazol-2-yl)-benzoic acid
  参考文献：
  名称：

  FISCHER; HURNI, Arzneimittel-Forschung/Drug Research, 1964, vol. 14, p. 1301 - 1306

  摘要：

  DOI：

文献信息

• [EN] PHARMACEUTICAL FORMULATIONS<br/>[FR] FORMULATIONS PHARMACEUTIQUES
  申请人：MOLECULAR DEFENSES CORP

  公开号：WO2017091737A1

  公开（公告）日：2017-06-01

  Disclosed herein is glutathione in conjunction with an isoselenazol or isothiazol derivative, e.g., ebselen or ebsulfur derivative, to treat diabetes, lupus, or other chronic inflammatory disease. The glutathione is preferably provided in a rapid release oral formulation that presents the glutathione for absorption in the first part of the ileum. The isoselenazol or isothiazol derivative is preferably provided in a delayed release formulation to avoid overlapping high enteric concentration. These may be provided within the same unit dosage form.

  本文披露了谷胱甘肽与异硒唑或异硫唑衍生物（例如ebselen或ebsulfur衍生物）结合治疗糖尿病、狼疮或其他慢性炎症性疾病的方法。谷胱甘肽最好以快速释放口服制剂的形式提供，以便在回肠的第一部分中吸收谷胱甘肽。异硒唑或异硫唑衍生物最好以延迟释放制剂的形式提供，以避免重叠的高肠内浓度。这些可以在同一单位剂量形式中提供。
• Antibiotic compositions
  申请人：Holmgren Arne

  公开号：US10653717B2

  公开（公告）日：2020-05-19

  Disclosed herein are antibiotic compositions, for example compositions that comprise a metal-containing agent and an organoselenium agent, and uses thereof.

  本文公开了抗生素组合物，例如包含含金属剂和有机硒剂的组合物及其用途。
• Composition comprising selenazol or thiazalone derivatives and silver and method of treatment therewith
  申请人：Thioredoxin Systems AB

  公开号：US11013730B1

  公开（公告）日：2021-05-25

  A method for treating a prokaryotic infection in an animal or human by administering a pharmaceutically acceptable composition, comprising administering a source of silver ions and a benzoisoselenazol derivative, e.g., an ebselen derivative.

  一种通过施用药学上可接受的组合物治疗动物或人类原核细胞感染的方法，包括施用银离子源和苯并异硒唑衍生物，例如依布硒衍生物。
• Antibiotic Compositions
  申请人：Holmgren Arne

  公开号：US20180185410A1

  公开（公告）日：2018-07-05

  Disclosed herein are antibiotic compositions, for example compositions that comprise a metal-containing agent and an organoselenium agent, and uses thereof.
• PHARMACEUTICAL FORMULATIONS
  申请人：Molecular Defenses Corporation

  公开号：US20190307726A1

  公开（公告）日：2019-10-10

  Disclosed herein is glutathione in conjunction with an isoselenazol or isothiazol derivative, e.g., ebselen or ebsulfur derivative, to treat diabetes, lupus, or other chronic inflammatory disease. The glutathione is preferably provided in a rapid release oral formulation that presents the glutathione for absorption in the first part of the ileum. The isoselenazol or isothiazol derivative is preferably provided in a delayed release formulation to avoid overlapping high enteric concentration. These may be provided within the same unit dosage form.

表征谱图